Company intelligence / Profile preview

Alnivo Therapeutics

Mansfield, Massachusetts, United Statesbioinc.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Alnivo Therapeutics focuses on researching the therapeutic and cosmetic potential of Heat-Shock Protein 70 (HSP70), targeting applications such as anti-aging, scar and wound healing, and treatment of various skin diseases. No clinical results have been published yet[4][6].

Therapeutic areas: OtherDermatology
Modalities: Protein therapeutics (Heat-Shock Protein 70, HSP70)
Industry: Biotech

Beyond the preview

Go deeper on Alnivo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alnivo Therapeutics.

Explore the full profile